Treatment of Secondary Mitral Regurgitation via Percutaneous Annuloplasty - European Medical Journal

Continue

Treatment of Secondary Mitral Regurgitation via Percutaneous Annuloplasty

Interventional Cardiology
Download PDF

This symposium took place on 21st May 2015 (13:35-14:35), as part of EuroPCR 2015; the official annual meeting of the European Association for Percutaneous Cardiovascular Interventions (EAPCI)

Chairperson:
Michael Haude1
Speakers:
Christian Spaulding,2 Stephan Fichtlscherer,3 Christoph Hammerstingl4

1. Medical Clinic I, Neuss City Clinic, Lukas Krankenhaus GmbH, Neuss, Germany 
2. European Hospital Georges Pompidou and INSERM U 970, Paris Descartes University, Paris, France 
3. Department of Internal Medicine III / Division of Cardiology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany 
4. Heart Center, University of Bonn, Bonn, Germany

Disclosure:

Michael Haude has acted as consultant for Biotronik, Cardiac Dimensions, and OrbusNeich. He has received honoraria from Abbott Vascular, AstraZeneca, Biotronik, Daiichi Sankyo and Eli Lilly, Direct Flow Medical, Medtronic, and Volcano. He has received an institutional grant/research support from Abbott Vascular, Biotronik, and Cardiac Dimensions. Christian Spaulding has acted as consultant for Abiomed, GE Healthcare, Medtronic, and Zoll. He has received honoraria from AstraZeneca, Bayer Healthcare Pharmaceuticals, Biosense Webster, Johnson & Johnson and Cordis, Johnson & Johnson, Biosensors International, Lilly, The Medicines Company, and Servier. Stephan Fichtlscherer has acted as consultant for ACIST Medical Systems, Edwards Lifesciences, Siemens, Volcano, and Cardiac Dimensions. He has received honoraria from Cardiac Dimensions. Christoph Hammerstingl has received honoraria from AstraZeneca, Bayer Healthcare Pharmaceuticals, Cardiac Dimensions, Medtronic Academia, and Mitralign. He has received an institutional grant/research support from Abbott Vascular.

Acknowledgements:

Writing assistance was provided by Dr Jill Powell, apothecom scopemedical Ltd.

Support:

The publication of this article was funded by Cardiac Dimensions. The views and opinions expressed are those of the authors and not necessarily of Cardiac Dimensions.

Citation:
EMJ Int Cardiol. ;3[1]:39-45. DOI/10.33590/emjintcardiol/10310810. https://doi.org/10.33590/emjintcardiol/10310810.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Meeting Summary

Functional mitral regurgitation (FMR) is a common occurrence in patients with heart failure (HF). FMR is associated with as much as a 2-fold increase in mortality, as well as in HF hospitalisations. Over the past 15 years, efforts to address FMR have focussed on the development of transcatheter devices that replicate the effect of annuloplasty; however, besides open heart surgery, optimal medical treatment remains the standard of care (SoC) for these patients. To date, the only CE-marked option available for clinical use as a transcatheter annuloplasty device is the CARILLON® Contour System® from Cardiac Dimensions. The efficacy demonstrated in clinical trials, implantation technique, and comprehensive patient treatment was discussed during the symposium at EuroPCR and is presented in detail in this article.

Please view the full content in the pdf above.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.